Cargando…
Tumour budding and tumour–stroma ratio in hepatocellular carcinoma
BACKGROUND: Tumour budding and low tumour–stroma ratio (TSR) are associated with poor prognosis in some cancers, but their value in Western hepatocellular carcinoma is unclear. The prognostic value of tumour budding and TSR in hepatocellular carcinoma was examined. METHODS: Some 259 hepatocellular c...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7341881/ https://www.ncbi.nlm.nih.gov/pubmed/32362654 http://dx.doi.org/10.1038/s41416-020-0847-1 |
_version_ | 1783555325273571328 |
---|---|
author | Kairaluoma, Valtteri Kemi, Niko Pohjanen, Vesa-Matti Saarnio, Juha Helminen, Olli |
author_facet | Kairaluoma, Valtteri Kemi, Niko Pohjanen, Vesa-Matti Saarnio, Juha Helminen, Olli |
author_sort | Kairaluoma, Valtteri |
collection | PubMed |
description | BACKGROUND: Tumour budding and low tumour–stroma ratio (TSR) are associated with poor prognosis in some cancers, but their value in Western hepatocellular carcinoma is unclear. The prognostic value of tumour budding and TSR in hepatocellular carcinoma was examined. METHODS: Some 259 hepatocellular carcinoma patients treated in Oulu University Hospital 1983–2018 were included in this retrospective cohort study. Tumour budding and TSR were analysed from the haematoxylin- and eosin-stained original diagnostic slides, by dividing patients into bud-negative (0 bud) or bud-positive (≥1 bud) groups, and into high TSR (<50%) and low TSR (≥50%) groups. Surgically treated patients (n = 47) and other treatments (n = 212) were analysed separately. Primary outcomes were overall, and disease-specific 5-year mortality was adjusted for confounding factors. RESULTS: Surgically treated patients with positive tumour budding had increased 5-year overall (adjusted HR 3.87, 95% CI 1.10–13.61) and disease-specific (adjusted HR 6.17, 95% CI 1.19–31.90) mortality compared with bud-negative patients. In surgically treated patients, TSR had no effect on 5-year overall (adjusted HR 2.03, 95% CI 0.57–7.21) or disease-specific (adjusted HR 3.23, 95% CI 0.78–13.37) mortality. No difference in survival related to tumour budding and TSR in non-surgically treated patients was observed. CONCLUSIONS: Tumour budding is a prognostic factor in surgically treated hepatocellular carcinoma. |
format | Online Article Text |
id | pubmed-7341881 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-73418812021-05-04 Tumour budding and tumour–stroma ratio in hepatocellular carcinoma Kairaluoma, Valtteri Kemi, Niko Pohjanen, Vesa-Matti Saarnio, Juha Helminen, Olli Br J Cancer Article BACKGROUND: Tumour budding and low tumour–stroma ratio (TSR) are associated with poor prognosis in some cancers, but their value in Western hepatocellular carcinoma is unclear. The prognostic value of tumour budding and TSR in hepatocellular carcinoma was examined. METHODS: Some 259 hepatocellular carcinoma patients treated in Oulu University Hospital 1983–2018 were included in this retrospective cohort study. Tumour budding and TSR were analysed from the haematoxylin- and eosin-stained original diagnostic slides, by dividing patients into bud-negative (0 bud) or bud-positive (≥1 bud) groups, and into high TSR (<50%) and low TSR (≥50%) groups. Surgically treated patients (n = 47) and other treatments (n = 212) were analysed separately. Primary outcomes were overall, and disease-specific 5-year mortality was adjusted for confounding factors. RESULTS: Surgically treated patients with positive tumour budding had increased 5-year overall (adjusted HR 3.87, 95% CI 1.10–13.61) and disease-specific (adjusted HR 6.17, 95% CI 1.19–31.90) mortality compared with bud-negative patients. In surgically treated patients, TSR had no effect on 5-year overall (adjusted HR 2.03, 95% CI 0.57–7.21) or disease-specific (adjusted HR 3.23, 95% CI 0.78–13.37) mortality. No difference in survival related to tumour budding and TSR in non-surgically treated patients was observed. CONCLUSIONS: Tumour budding is a prognostic factor in surgically treated hepatocellular carcinoma. Nature Publishing Group UK 2020-05-04 2020-07-07 /pmc/articles/PMC7341881/ /pubmed/32362654 http://dx.doi.org/10.1038/s41416-020-0847-1 Text en © The Author(s), under exclusive licence to Cancer Research UK 2020 https://creativecommons.org/licenses/by/4.0/Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0). |
spellingShingle | Article Kairaluoma, Valtteri Kemi, Niko Pohjanen, Vesa-Matti Saarnio, Juha Helminen, Olli Tumour budding and tumour–stroma ratio in hepatocellular carcinoma |
title | Tumour budding and tumour–stroma ratio in hepatocellular carcinoma |
title_full | Tumour budding and tumour–stroma ratio in hepatocellular carcinoma |
title_fullStr | Tumour budding and tumour–stroma ratio in hepatocellular carcinoma |
title_full_unstemmed | Tumour budding and tumour–stroma ratio in hepatocellular carcinoma |
title_short | Tumour budding and tumour–stroma ratio in hepatocellular carcinoma |
title_sort | tumour budding and tumour–stroma ratio in hepatocellular carcinoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7341881/ https://www.ncbi.nlm.nih.gov/pubmed/32362654 http://dx.doi.org/10.1038/s41416-020-0847-1 |
work_keys_str_mv | AT kairaluomavaltteri tumourbuddingandtumourstromaratioinhepatocellularcarcinoma AT keminiko tumourbuddingandtumourstromaratioinhepatocellularcarcinoma AT pohjanenvesamatti tumourbuddingandtumourstromaratioinhepatocellularcarcinoma AT saarniojuha tumourbuddingandtumourstromaratioinhepatocellularcarcinoma AT helminenolli tumourbuddingandtumourstromaratioinhepatocellularcarcinoma |